B. Lauri

发表

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

G. Birgegard, P. Näsman, A. Österborg, 2007, Leukemia.

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

G. Birgegard, P. Näsman, A. Österborg, 2008, Leukemia.

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

E. Kimby, H. Johansson, J. Klintman, 2018, Haematologica.

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

A. Österborg, B. Lauri, J. Lundin, 2016, Haematologica.

Prevalence of sexually transmitted infections in female clinic attendees in Honiara, Solomon Islands

D. Mabey, A. Solomon, B. Lauri, 2015, BMJ Open.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

M. Beksac, M. Dimopoulos, B. Pégourié, 2019, The Lancet.

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population

U. Mellqvist, G. Gahrton, H. Nahi, 2014, British journal of haematology.

Solomon Islands in female clinic attendees in Honiara , Prevalence of sexually transmitted infections

D. Mabey, A. Solomon, B. Lauri, 2015 .

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study

G. Juliusson, H. Nahi, I. Turesson, 2021, Cancer reports.

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

P. Sonneveld, A. Chanan-Khan, H. Avet-Loiseau, 2020, Journal of Hematology & Oncology.

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

R. Rosenquist, A. Österborg, B. Lauri, 2018, Haematologica.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

P. Sonneveld, A. Chanan-Khan, H. Avet-Loiseau, 2018, Haematologica.

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma

U. Mellqvist, G. Gahrton, H. Nahi, 2018, Cancer medicine.

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

M. Bøgsted, K. Dybkær, U. Mellqvist, 2022, BMC cancer.

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

H. Nahi, A. Waage, M. Hansson, 2020 .

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

Henrik Gréen, Karin Forsberg, U. Mellqvist, 2017, Cancer Chemotherapy and Pharmacology.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

P. Sonneveld, A. Chanan-Khan, H. Avet-Loiseau, 2018, Haematologica.